Incyte (INCY) Total Non-Current Liabilities (2013 - 2026)

Incyte (INCY) posted Total Non-Current Liabilities of $1.6 billion for Q1 2026, down 2.19% on a QoQ basis from $1.6 billion in Q4 2025, and down 16.61% year-over-year from $1.9 billion in Q1 2025.

Incyte (INCY) Total Non-Current Liabilities (2013 - 2026) Analysis & Trends

Incyte's Total Non-Current Liabilities history runs 14 years deep, the most recent figure standing at $1.6 billion for Q1 2026.

  • Quarterly Total Non-Current Liabilities fell 16.61% year-over-year to $1.6 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.6 billion (down 16.61% YoY) and the FY2025 annual result came in at $1.6 billion, down 11.15% from the prior year.
  • Total Non-Current Liabilities was $1.6 billion for Q1 2026 at Incyte, down from $1.6 billion in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $1.9 billion in Q1 2025 and bottomed at $987.0 million in Q1 2022.
  • A 5-year average of $1.5 billion and a median of $1.5 billion in 2025 frame the typical range for Total Non-Current Liabilities.
  • Annual changes were most pronounced in 2022 — Total Non-Current Liabilities surged 54.44% — and 2026, when it fell 16.61%.
  • Incyte's Total Non-Current Liabilities stood at $1.3 billion in 2022, then gained by 12.18% to $1.4 billion in 2023, then increased by 26.75% to $1.8 billion in 2024, then dropped by 11.15% to $1.6 billion in 2025, then slipped by 2.19% to $1.6 billion in 2026.
  • Business Quant data shows INCY's Total Non-Current Liabilities at $1.6 billion in Q1 2026, $1.6 billion in Q4 2025, and $1.5 billion in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Non-Current Liabilities (Qtr)
1 Oculis Holding AG 67,072.09 Bn 67,072.09 Bn - 4.45 Mn
2 Nanobiotix 1,894.61 Bn 1,894.55 Bn - 110.28 Mn
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - 19.49 Mn
4 BeOne Medicines 471.64 Bn 466.85 Bn 1.35 Bn 1.98 Bn
5 Vertex Pharmaceuticals 121.72 Bn 114.47 Bn 2.59 Bn 5.87 Bn
6 Regeneron Pharmaceuticals 68.28 Bn 59.52 Bn 3.31 Bn 7.32 Bn
7 Belite Bio 61.40 Bn 61.40 Bn - -
8 Argenx Se 56.94 Bn 56.94 Bn 1.18 Bn -
9 Revolution Medicines 37.37 Bn 37.37 Bn - 746.94 Mn
10 Incyte 23.47 Bn 19.46 Bn 1.17 Bn 1.59 Bn

Historic Data

Download Data
DateValue
Mar 31, 2026 1.59 Bn
Dec 31, 2025 1.63 Bn
Sep 30, 2025 1.51 Bn
Jun 30, 2025 1.47 Bn
Mar 31, 2025 1.91 Bn
Dec 31, 2024 1.83 Bn
Sep 30, 2024 1.67 Bn
Jun 30, 2024 1.52 Bn
Mar 31, 2024 1.59 Bn
Dec 31, 2023 1.44 Bn
Sep 30, 2023 1.32 Bn
Jun 30, 2023 1.33 Bn
Mar 31, 2023 1.22 Bn
Dec 31, 2022 1.29 Bn
Sep 30, 2022 1.21 Bn
Jun 30, 2022 1.16 Bn
Mar 31, 2022 987.02 Mn
Dec 31, 2021 1.09 Bn
Sep 30, 2021 987.87 Mn
Jun 30, 2021 749.75 Mn